|
1
|
Lindvig KP, Teisner AS, Kjeldsen J, Strøm
T, Toft P, Furhmann V and Krag A: Allocation of patients with liver
cirrhosis and organ failure to intensive care: Systematic review
and a proposal for clinical practice. World J Gastroenterol.
21:8964–8973. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reddy SS and Civan JM: From child-pugh to
model for end-stage liver disease: Deciding who needs a liver
transplant. Med Clin North Am. 100:449–464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lai YH, Duan WD, Yu Q, Ye S, Xiao NJ,
Zhang DX, Huang ZQ, Yang ZY and Dong JH: Outcomes of liver
transplantation for end-stage biliary disease: A comparative study
with end-stage liver disease. World J Gastroenterol. 21:6296–6303.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gong N and Chen X: Partial liver
transplantation. Front Med. 5:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raut V, Alikhanov R, Belghiti J and Uemoto
S: Review of the surgical approach to prevent small-for-size
syndrome in recipients after left lobe adult LDLT. Surg Today.
44:1189–1196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nicolas CT, Wang Y and Nyberg SL: Cell
therapy in chronic liver disease. Curr Opin Gastroenterol.
32:189–194. 2016.PubMed/NCBI
|
|
7
|
Than NN, Tomlinson CL, Haldar D, King AL,
Moore D and Newsome PN: Clinical effectiveness of cell therapies in
patients with chronic liver disease and acute-on-chronic liver
failure: A systematic review protocol. Syst Rev. 5:1002016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malhotra S, Hu MS, Marshall CD, Leavitt T,
Cheung AT, Gonzalez JG, Kaur H, Lorenz HP and Longaker MT:
Mesenchymal stromal cells as cell-based therapeutics for wound
healing. Stem Cells Int. 2016:41579342016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Prockop DJ: Inflammation, fibrosis and
modulation of the process by mesenchymal stem/stromal cells. Matrix
Biol. 51:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK,
Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, et al: Transplantation
with autologous bone marrow-derived mesenchymal stem cells for
alcoholic cirrhosis: Phase 2 trial. Hepatology. 64:2185–2197. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW,
Cho MY, Park HJ, Park SY, Kim BR, Kim JW, et al: Histological
improvement following administration of autologous bone
marrow-derived mesenchymal stem cells for alcoholic cirrhosis: A
pilot study. Liver Int. 34:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salama H, Zekri AR, Medhat E, Al Alim SA,
Ahmed OS, Bahnassy AA, Lotfy MM, Ahmed R and Musa S: Peripheral
vein infusion of autologous mesenchymal stem cells in Egyptian
HCV-positive patients with end-stage liver disease. Stem Cell Res
Ther. 5:702014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du Z, Wei C, Yan J, Han B, Zhang M, Peng C
and Liu Y: Mesenchymal stem cells overexpressing C-X-C chemokine
receptor type 4 improve early liver regeneration of small-for-size
liver grafts. Liver Transpl. 19:215–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maria AT, Maumus M, Le Quellec A,
Jorgensen C, Noël D and Guilpain P: Adipose-derived mesenchymal
stem cells in autoimmune disorders: State of the art and
perspectives for systemic sclerosis. Clin Rev Allergy Immunol.
52:234–259. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu T, Mu H, Shen Z, Song Z, Chen X and
Wang Y: Autologous adipose tissue-derived mesenchymal stem cells
are involved in rat liver regeneration following repeat partial
hepatectomy. Mol Med Rep. 13:2053–2059. 2016.PubMed/NCBI
|
|
16
|
Mancini O Kizilay, Shum-Tim D, Stochaj U,
Correa JA and Colmegna I: Age, atherosclerosis and type 2 diabetes
reduce human mesenchymal stromal cell-mediated T-cell suppression.
Stem Cell Res Ther. 6:1402015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang YL, Li G, Zou XF, Chen XB, Liu T and
Shen ZY: Effect of autologous adipose-derived stem cells in renal
cold ischemia and reperfusion injury. Transplant Proc.
45:3198–3202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu T, Zhang Y, Shen Z, Song Z, Zou X,
Chen X, Chen L and Wang Y: Immunomodulatory effects of OX40Ig
gene-modified adipose tissue-derived mesenchymal stem cells in rat
kidney transplantation. Int J Mol Med. 39:144–152. 2017.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu YE, Du ZR, Cai YM, Peng WG, Zheng GZ,
Zheng GL, Wu LB and Li K: Effective expansion of forkhead box
P3+ regulatory T cells via early secreted antigenic
target 6 and antigen 85 complex B from Mycobacterium
tuberculosis. Mol Med Rep. 11:3134–3142. 2015.PubMed/NCBI
|
|
21
|
Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J,
Chen L, Lv S, Li Y, Yu S, et al: Human umbilical cord mesenchymal
stem cells improve liver function and ascites in decompensated
liver cirrhosis patients. J Gastroenterol Hepatol. 27:(Suppl 2).
S112–S120. 2012. View Article : Google Scholar
|
|
22
|
Choudhery MS, Badowski M, Muise A, Pierce
J and Harris DT: Donor age negatively impacts adipose
tissue-derived mesenchymal stem cell expansion and differentiation.
J Transl Med. 12:82014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harasymiak-Krzyżanowska I, Niedojadło A,
Karwat J, Kotuła L, Gil-Kulik P, Sawiuk M and Kocki J: Adipose
tissue-derived stem cells show considerable promise for
regenerative medicine applications. Cell Mol Biol Lett. 18:479–493.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schneider S, Unger M, van Griensven M and
Balmayor ER: Adipose-derived mesenchymal stem cells from
liposuction and resected fat are feasible sources for regenerative
medicine. Eur J Med Res. 22:172017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Efimenko A, Dzhoyashvili N, Kalinina N,
Kochegura T, Akchurin R, Tkachuk V and Parfyonova Y:
Adipose-derived mesenchymal stromal cells from aged patients with
coronary artery disease keep mesenchymal stromal cell properties
but exhibit characteristics of aging and have impaired angiogenic
potential. Stem Cells Transl Med. 3:32–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu W, Niklason L and Steinbacher DM: The
effect of age on human adipose-derived stem cells. Plast Reconstr
Surg. 131:27–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yarygin KN, Lupatov AY and Kholodenko IV:
Cell-based therapies of liver diseases: Age-related challenges.
Clin Interv Aging. 10:1909–1924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai A, Qiu R, Li L, Zheng D, Dong Y, Yu D,
Huang Y, Rao S, Zhou Y and Mai W: Atorvastatin treatment of rats
with ischemia-reperfusion injury improves
adipose-derivedmesenchymal stem cell migration and survival via the
SDF-1α/CXCR-4 axis. PLoS One. 8:e791002013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lai SL, Cheah SC, Wong PF, Noor SM and
Mustafa MR: In vitro and in vivo anti-angiogenic activities of
Panduratin A. PLoS One. 7:e381032012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ong WK and Sugii S: Adipose-derived stem
cells: Fatty potentials for therapy. Int J Biochem Cell Biol.
45:1083–1086. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kornicka K, Marycz K, Tomaszewski KA,
Marędziak M and Śmieszek A: The effect of age on osteogenic and
adipogenic differentiation potential of human adipose derived
stromal stem cells (hASCs) and the impact of stress factors in the
course of the differentiation process. Oxid Med Cell Longev.
2015:3091692015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Beane OS, Fonseca VC, Cooper LL, Koren G
and Darling EM: Impact of aging on the regenerative properties of
bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal
cells. PLoS One. 9:e1159632014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sethe S, Scutt A and Stolzing A: Aging of
mesenchymal stem cells. Ageing Res Rev. 5:91–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Owen A and Newsome PN: Mesenchymal stromal
cell therapy in liver disease: Opportunities and lessons to be
learnt? Am J Physiol Gastrointest Liver Physiol. 309:G791–G800.
2015.PubMed/NCBI
|
|
35
|
Petrou P, Gothelf Y, Argov Z, Gotkine M,
Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky
O, et al: Safety and clinical effects of mesenchymal stem cells
secreting neurotrophic factor transplantation in patients with
amyotrophic lateral sclerosis: Results of phase 1/2 and 2a clinical
trials. JAMA Neurol. 73:337–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mizuno M, Katano H, Otabe K, Komori K,
Matsumoto Y, Fujii S, Ozeki N, Tsuji K, Koga H, Muneta T, et al:
Platelet-derived growth factor (PDGF)-AA/AB in human serum are
potential indicators of the proliferative capacity of human
synovial mesenchymal stem cells. Stem Cell Res Ther. 6:2432015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kavanagh DP, Suresh S, Newsome PN,
Frampton J and Kalia N: Pretreatment of mesenchymal stem cells
manipulates their vasculoprotective potential while not altering
their homing within the injured gut. Stem Cells. 33:2785–2797.
2015. View Article : Google Scholar : PubMed/NCBI
|
